Characterization and response of newly developed high-grade glioma cultures to the tyrosine kinase inhibitors, erlotinib, gefitinib and imatinib (Q48687589)

From Wikidata

Jump to navigation Jump to search

scientific article published on 20 January 2012

Language	Label	Description	Also known as
English	Characterization and response of newly developed high-grade glioma cultures to the tyrosine kinase inhibitors, erlotinib, gefitinib and imatinib	scientific article published on 20 January 2012

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

14 February 2018

http://europepmc.org/abstract/MED/22285130

Characterization and response of newly developed high-grade glioma cultures to the tyrosine kinase inhibitors, erlotinib, gefitinib and imatinib (English)

1 reference

Europe PubMed Central

PubMed publication ID

14 February 2018

http://europepmc.org/abstract/MED/22285130

1 reference

based on heuristic

inferred from title

4

1 reference

Europe PubMed Central

PubMed publication ID

14 February 2018

http://europepmc.org/abstract/MED/22285130

author name string

Paula Kinsella

1

1 reference

Europe PubMed Central

PubMed publication ID

14 February 2018

http://europepmc.org/abstract/MED/22285130

Rachel Howley

2

1 reference

Europe PubMed Central

PubMed publication ID

14 February 2018

http://europepmc.org/abstract/MED/22285130

Padraig Doolan

3

1 reference

Europe PubMed Central

PubMed publication ID

14 February 2018

http://europepmc.org/abstract/MED/22285130

Stephen F Madden

5

1 reference

Europe PubMed Central

PubMed publication ID

14 February 2018

http://europepmc.org/abstract/MED/22285130

Martin Clynes

6

1 reference

Europe PubMed Central

PubMed publication ID

14 February 2018

http://europepmc.org/abstract/MED/22285130

Michael Farrell

7

1 reference

Europe PubMed Central

PubMed publication ID

14 February 2018

http://europepmc.org/abstract/MED/22285130

Verena Amberger-Murphy

8

1 reference

Europe PubMed Central

PubMed publication ID

14 February 2018

http://europepmc.org/abstract/MED/22285130

language of work or name

0 references

publication date

20 January 2012

1 reference

Europe PubMed Central

PubMed publication ID

14 February 2018

http://europepmc.org/abstract/MED/22285130

Experimental Cell Research

1 reference

Europe PubMed Central

PubMed publication ID

14 February 2018

http://europepmc.org/abstract/MED/22285130

318

1 reference

Europe PubMed Central

PubMed publication ID

14 February 2018

http://europepmc.org/abstract/MED/22285130

5

1 reference

Europe PubMed Central

PubMed publication ID

14 February 2018

http://europepmc.org/abstract/MED/22285130

641-652

1 reference

Europe PubMed Central

PubMed publication ID

14 February 2018

http://europepmc.org/abstract/MED/22285130

Cell signaling by receptor tyrosine kinases

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.01.014

7 January 2021

Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.01.014

7 January 2021

Gastrointestinal stromal tumors (GIST): C-kit mutations, CD117 expression, differential diagnosis and targeted cancer therapy with imatinib

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.01.014

7 January 2021

Targeted signal transduction therapies in myeloid malignancies

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.01.014

7 January 2021

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.01.014

7 January 2021

Epithelial Growth Factor Receptor Inhibitors for treatment of recurrent or progressive high grade glioma: an exploratory study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.01.014

7 January 2021

A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.01.014

7 January 2021

Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.01.014

7 January 2021

Phase II study of neoadjuvant imatinib in glioblastoma: evaluation of clinical and molecular effects of the treatment

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.01.014

7 January 2021

EGFR mutations and sensitivity to gefitinib

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.01.014

7 January 2021

Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.01.014

7 January 2021

Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.01.014

7 January 2021

Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.01.014

7 January 2021

Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.01.014

7 January 2021

Genetic alterations and signaling pathways in the evolution of gliomas

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.01.014

7 January 2021

Malignant astrocytic glioma: genetics, biology, and paths to treatment

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.01.014

7 January 2021

Astrocytoma derived short-term cell cultures retain molecular signatures characteristic of the tumour in situ.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.01.014

7 January 2021

Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.01.014

7 January 2021

Automated network analysis identifies core pathways in glioblastoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.01.014

7 January 2021

The phosphatidylinositol 3-Kinase AKT pathway in human cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.01.014

7 January 2021

The epidermal growth factor receptor as a therapeutic target in glioblastoma multiforme and other malignant neoplasms

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.01.014

7 January 2021

Isolation from a human MDR lung cell line of multiple clonal subpopulations which exhibit significantly different drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.01.014

7 January 2021

Inhibition by erlotinib of primary lung adenocarcinoma at an early stage in male mice.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.01.014

7 January 2021

Lovastatin enhances gefitinib activity in glioblastoma cells irrespective of EGFRvIII and PTEN status

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.01.014

7 January 2021

Gefitinib concentrations in human glioblastoma tissue

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.01.014

7 January 2021

Increased sensitivity to the platelet-derived growth factor (PDGF) receptor inhibitor STI571 in chemoresistant glioma cells is associated with enhanced PDGF-BB-mediated signaling and STI571-induced Akt inactivation

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.01.014

7 January 2021

Imatinib and docetaxel in combination can effectively inhibit glioma invasion in an in vitro 3D invasion assay

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.01.014

7 January 2021

AKT activation in human glioblastomas enhances proliferation via TSC2 and S6 kinase signaling.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.01.014

7 January 2021

Histologic and immunohistochemical decision-making in endometrial adenocarcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.01.014

7 January 2021

ATM protein expression correlates with radioresistance in primary glioblastoma cells in culture

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.01.014

7 January 2021

In vitro techniques for the assessment of neurotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.01.014

7 January 2021

Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.01.014

7 January 2021

Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.01.014

7 January 2021

Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.01.014

7 January 2021

Influence of breast cancer resistance protein (Abcg2) and p-glycoprotein (Abcb1a) on the transport of imatinib mesylate (Gleevec® ) across the mouse blood-brain barrier

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.01.014

7 January 2021

Role of ATP-Binding Cassette and Solute Carrier Transporters in Erlotinib CNS Penetration and Intracellular Accumulation

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.01.014

7 January 2021

Plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite OSI-420.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.01.014

7 January 2021

Contrasting in vivo and in vitro fates of glioblastoma cell subpopulations with amplified EGFR

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.01.014

7 January 2021

Glioblastoma-derived spheroid cultures as an experimental model for analysis of EGFR anomalies.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.01.014

7 January 2021

Prognostic but not predictive role of platelet-derived growth factor receptors in patients with recurrent glioblastoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.01.014

7 January 2021

Functional validation confirms genomic phenotypes of glioblastoma with implications for targeted therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.01.014

7 January 2021

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.01.014

7 January 2021

Different response of human glioma tumor-initiating cells to epidermal growth factor receptor kinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.01.014

7 January 2021

Small tyrosine kinase inhibitors interrupt EGFR signaling by interacting with erbB3 and erbB4 in glioblastoma cell lines.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.01.014

7 January 2021

Analysis of EGFR gene amplification, protein over-expression and tyrosine kinase domain mutation in recurrent glioblastoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.01.014

7 January 2021

Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.01.014

7 January 2021

Overexpression and Amplification of .ALPHA.-PDGF Receptor Gene Lacking Exons Coding for a Portion of the Extracellular Region in a Malignant Glioma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.01.014

7 January 2021

Amplification of the platelet-derived growth factor receptor-A (PDGFRA) gene occurs in oligodendrogliomas with grade IV anaplastic features.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.01.014

7 January 2021

Expression of PDGF and PDGF receptors in human astrocytoma operation specimens supports the existence of an autocrine loop.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.01.014

7 January 2021

Comparative molecular genetic profiles of anaplastic astrocytomas/glioblastomas multiforme and their subsequent recurrences.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.01.014

7 January 2021

Characterization of an imatinib-sensitive subset of high-grade human glioma cultures

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.01.014

7 January 2021

Imatinib mesylate radiosensitizes human glioblastoma cells through inhibition of platelet-derived growth factor receptor.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.01.014

7 January 2021

Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.01.014

7 January 2021

Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.01.014

7 January 2021

RAS/RAF pathway activation in gliomas: the result of copy number gains rather than activating mutations

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.01.014

7 January 2021

EGFR signals to mTOR through PKC and independently of Akt in glioma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.01.014

7 January 2021

Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.01.014

7 January 2021

Convection-Enhanced Delivery of Topotecan into a PDGF-Driven Model of Glioblastoma Prolongs Survival and Ablates Both Tumor-Initiating Cells and Recruited Glial Progenitors

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.01.014

7 January 2021

Convection-enhanced delivery of free gadolinium with the recombinant immunotoxin MR1-1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.01.014

7 January 2021

Identifiers

10.1016/J.YEXCR.2012.01.014

1 reference

Europe PubMed Central

PubMed publication ID

14 February 2018

http://europepmc.org/abstract/MED/22285130

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

14 February 2018

http://europepmc.org/abstract/MED/22285130

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48687589&oldid=2249138880"